First phase I trial of influenza A virus H1N1 vaccine in Singapore.

Trial Profile

First phase I trial of influenza A virus H1N1 vaccine in Singapore.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2014

At a glance

  • Drugs Qb Flu (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 01 Feb 2014 Status changed from active, no longer recruiting to completed.
    • 29 Jan 2014 Results have been reported in a Cytos Biotechnology and Singapore Agency for Science, Technology and research media release.
    • 29 Jan 2014 Primary endpoint 'Immunological-response' (Immunogenicity as demonstrated by seroconversion based on haemaglutination inhibition titres according to FDA criteria) has been met according a Cytos Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top